BCM
RCUS icon

Bayesian Capital Management’s Arcus Biosciences RCUS Stock Holding History

Bayesian Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,200
Closed -$111K – 816
2025
Q1 		$111K Buy
+14,200
New +$165K 0.02% 537
2024
Q3 		– Sell
-24,100
Closed -$367K – 981
2024
Q2 		$367K Buy
+24,100
New +$389K 0.04% 453
2022
Q3 		– Sell
-13,736
Closed -$348K – 967
2022
Q2 		$348K Buy
+13,736
New +$336K 0.06% 430

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Bayesian Capital Management's RCUS Position: Q2 2025 in Review

Bayesian Capital Management sold out of Arcus Biosciences (RCUS) in Q2 2025, closing a stake of 14,200 shares — an estimated $111K sold.

Bayesian Capital Management first reported a position in RCUS in Q2 2022 and held it in 3 quarters. The position peaked at $367K in Q2 2024. 185 funds tracked by Wall St. Rank hold RCUS as of Q2 2025.

  • Bayesian Capital Management reported no remaining Arcus Biosciences position as of Q2 2025 after selling out during the quarter.
  • Bayesian Capital Management sold 14,200 Arcus Biosciences shares in Q2 2025, an estimated $111K.
  • Bayesian Capital Management first reported a position in Arcus Biosciences in Q2 2022 and held it in 3 quarters.
  • Bayesian Capital Management's Arcus Biosciences position peaked at $367K in Q2 2024.
  • 185 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2025.

Based on Bayesian Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.